Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FOLFOX and Bevacizumab With or Without Irinotecan in First-line Treatment for Metastatic Colorectal Cancer. A Randomized Phase II Study

Next Previous
X
Search
Trial Profile

FOLFOX and Bevacizumab With or Without Irinotecan in First-line Treatment for Metastatic Colorectal Cancer. A Randomized Phase II Study

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 28 Nov 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Irinotecan (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms CHARTA

    • Most Recent Events

    • 23 Nov 2023 Final results evaluating efficacy and quality of life for FOLFOX/bevacizumab with or without irinotecan in first-line metastatic colorectal cancer published in the British Journal of Cancer.
    • 24 Oct 2023 Results assessing to predict which patients with metastatic colorectal cancer will benefit from first-line FOLFOXIRI versus FOLFOX/FOLFIRI, both plus bevacizumab from phase III TRIBE2 (n=639) and the phase II CHARTA (n=232) trials, presented at the 48th European Society for Medical Oncology Congress.
    • 21 Sep 2020 Results of systemic review and meta analysis comparing efficacy FOLFOXIRI and doublets with targeted therapy in pts with mBRAF mCRC in terms of progression free survival, objective response rate and overall survival presented at the 45th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top